A Randomised Three-way Cross Over Study to Determine the Optimal Absorption of an Omega-3 Supplement Administered as a Single Oral Dose to Healthy Volunteers

This is a randomised three-way cross over study comparing the optimal absorption of a single dose of fish oil using 3 different forms to one another on increasing blood concentrations of fatty acids in 24 healthy adult participants aged 19 years and over.

开始日期2022-08-04

申办/合作机构

RDC Clinical Pty Ltd

NCT05121766 / Terminated临床1期IIT

Feasibility Pilot Clinical Trial of Omega-3 (EPA+DHA) Supplement vs. Placebo for Post-Acute Sequelae of Coronavirus-19 (COVID-19) Recovery Among Health Care Workers

This is a two-arm, double blind randomized 12-week study to supplement omega-3 (Eicosapentaenoic acid - EPA + docosahexaenoic acid - DHA) among 100 adults (age 18+) who had coronavirus-19 (covid-19) and are experiencing possible after-effects from post-acute sequelae of covid-19 (also called post-covid syndrome or long covid syndrome).

开始日期2022-01-10

申办/合作机构

Ocean Medical Center Association, Inc.

NCT03574142 / Completed临床1期

A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Epanova® in Chinese Healthy Subjects Living in China

The purpose of this study is to explore the safety, tolerability, and PK of single and multiple doses of Epanova in healthy male and female Chinese subjects and to allow comparison of these parameters with the Western population studied to date.

开始日期2018-06-04

申办/合作机构

AstraZeneca PLC

100 项与奥米加-3羧酸相关的临床结果

登录后查看更多信息

100 项与奥米加-3羧酸相关的转化医学

登录后查看更多信息

100 项与奥米加-3羧酸相关的专利（医药）

登录后查看更多信息

1,819

项与奥米加-3羧酸相关的文献（医药）

2025-01-01·FOOD CHEMISTRY

Glyphosate detection based on Eu coordination polymer through competitive coordination

Article

作者: Li, Ping ; Wang, Yuan ; Yi, Linglong ; Pan, Qinhe ; Wu, Shangzai ; Ren, Guojian ; Tian, Xudong ; Zhou, Qi ; He, Danfeng

Glyphosate is a widely used herbicide in agriculture, leading to residues in food and water environments. These residues have been associated with heart disease and neurotoxicity. Therefore, it is urgent to develop new types of sensors for the detection of glyphosate residues. Here, a new coordination polymer, named as HNU-89, is synthesized by the assembly of Eu³⁺ and coumarin-3-carboxylic acid (HCCA). Benefiting from the hydrophobic ligands, HNU-89 can maintain its structure at pH 2-11. In view of that phosphoric groups in glyphosate molecules can coordinate with Eu³⁺ and compete with the HCCA ligand, according to the competitive coordination, the interaction weakens the red fluorescence of HNU-89 simultaneously enhancing the blue fluorescence of HCCA, which achieves the ratio fluorescence response for glyphosate detection. The limit of detection (LOD) is 0.08 ppm, meeting the requirements as a sensor. Furthermore, HNU-89 was utilized to detect glyphosate in soybean, corn, rice and tap water.

2024-12-31·The Journal of dermatological treatment

The adjuvant treatment role of ω-3 fatty acids by regulating gut microbiota positively in the acne vulgaris

Article

作者: Xu, Yong ; Liu, Fuming ; Jiang, Shiyu ; Lai, Jindong ; Chen, Lingna ; Tan, Xiaoqi ; Xiong, Xia ; Huang, Yaxin ; Deng, Yongqiong

Objectives:We aimed to explore the potential role of omega-3 (ω-3) fatty acids on acne vulgaris by modulating gut microbiota.Materials and Methods:We randomly divided the untreated acne patients into two groups with or without ω-3 fatty acids intervention for 12 weeks. The Sprague Dawley (SD) rats with acne model were given isotretinoin, ω-3 fatty acids or their combination respectively. Then the colonic contents samples of the drug intervention SD rats were transferred to the pseudo sterile rats with acne model. The severity of the disease was assessed by the Global Acne Grading System (GAGS) score of the patients, and the swelling rate of auricle and the pathological section of the rat with acne model. The 16S rDNA gene sequencing was performed to detect the alteration of the gut microbiota.Results:ω-3 fatty acids could increase the diversity of the gut microbiota and regulate the flora structure positively both in the patients and rats, increase the abundance of butyric acid producing bacteria and GAGS score in the patients, and alleviate the inflammation and comedones of rats.Conclusion:Supplementation of ω-3 fatty acids could alleviate the inflammation of acne vulgaris by increasing the abundance of butyric acid producing bacteria.

2024-12-09·Critical reviews in food science and nutrition

The impact of climate change on Omega-3 long-chain polyunsaturated fatty acids in bivalves

Review

作者: Cheong, Kit-Leong ; Tan, Kianann ; Tan, Karsoon ; Ransangan, Julian

Omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) have many health benefits to human. Increasing evidence have shown that climate change reduces the availability of plankton n-3 LC-PUFA to primary consumers which potentially reduces the availability of n-3 LC-PUFA to human. Since marine bivalves are an important source of n-3 LC-PUFA for human beings, and bivalve aquaculture completely depends on phytoplankton in ambient water as food, it is important to understand the impact of climate change on the lipid nutritional quality of bivalves. In this study, fatty acid profile of different bivalves (mussels, oysters, clams, scallops and cockles) from different regions (tropical, subtropical and temperate) and time (before 1990, 1991-1995, 1996-2000, 2001-2005, 2006-2010, 2011-2015, 2016-2020) were extracted from published literature to calculate various lipid nutritional quality indicators. The results of this study revealed that the effects of global warming and declines in aragonite saturation state on the lipid content and lipid indices of bivalves are highly dependent on the geographical region and bivalves. In general, global warming has the largest negative impact on the lipid content and indices of temperate bivalves, including decreasing the PUFA/SFA, EPA + DHA and n-3/n-6. However, global warming has a much smaller negative impact on lipid content and lipid indices in other regions. The declines of aragonite saturation state in seawater promotes the accumulation of lipid content in tropical and subtropical bivalves, but it compromised the PUFA/SFA, EPA + DHA and n-3/n-6 of bivalves in all regions. The findings of this study not only fill the knowledge gap of the impact of climate change on the lipid nutritional quality of bivalves, but also provide guidance for the establishment of bivalve aquaculture and fisheries management plans to mitigate the impact of climate change.

项与奥米加-3羧酸相关的新闻（医药）

2024-08-31

·药明康德

刚发Cell，又登Science！张锋团队连发重磅论文，两大领域迎来突破

▎药明康德内容团队编辑才刚发Cell，隔天又一篇Science论文上线。CRISPR基因编辑先驱之一、Broad研究所和MIT麦戈文脑科学研究所的张锋教授成为本周生命科学领域的焦点人物。在两项不同领域的研究中，张锋团队先后解析了真核基因编辑系统Fanzor的结构、发现细菌用一种颠覆认知的基因编码方式抵抗噬菌体的机制。这两篇论文讲了什么，对生命科学领域将带来怎样的影响？在这篇文章中，我们将为大家解析这两项进展的核心内容。 ▲张锋教授（图片来源：张锋实验室主页/MIT麦戈文脑科学研究所）真核生物的“CRISPR”——Fanzor蛋白结构第一篇发表于Cell的论文，要从张锋团队去年的一篇Nature重磅论文说起。我们知道，革命性的基因编辑系统CRISPR/Cas源于古菌和细菌的免疫系统。除了CRISPR，自然界里还有哪些可编程的RNA系统？ 2023年，张锋团队发表了又一项重要突破，他们首次在真核生物中发现了可编程的RNA引导系统，这个真核生物的“CRSIPR”就是Fanzor（Fz）蛋白。作为一种在真核生物中广泛存在的核酸内切酶，Fanzor蛋白可以在RNA指引下，使用邻近的非编码RNA（ωRNA）靶向剪切DNA的特定位点。由于Fanzor蛋白可通过系统编辑、引入突变组合来大幅提高活性，并且其在剪切目标DNA时不会波及邻近DNA、导致不必要的编辑，因此Fanzor具有成为高效基因编辑工具的潜力。 ▲Fanzor蛋白冷冻电镜结构（图片来源：张锋实验室）要想进一步改造、优化Fanzor，以提升其基因编辑的效率与准确性，掌握Fanzor的结构是重要前提。在发表于Cell的最新研究中，张锋团队就对3种不同真核生物的Fanzor结构进行了冷冻电镜解析。这3种Fanzor蛋白分别是：来自藻类Guillardia theta的GtFz1、来自真菌Spizellomyces punctatus的SpuFz1，以及寄生真菌Parasitella parasitica的PpFz1。需要指出的是，Fanzor蛋白分为Fz1和Fz2两个家族，而最新研究解析的3种蛋白都属于Fz1——它们体积要大得多，也可能有着独特的功能与作用机制。 ▲3种生物的Fanzor蛋白结构示意图（图片来源：参考资料[1]）在获得了不同构象状态的13个Fz1结构后，研究团队从这些结构中发现了它们在与ωRNA和DNA识别方面的保守与独特之处。具体来说，3个物种的Fz1复合物结构基本相似，并且虽然不同物种的ωRNA长度差异很大，但这3种Fz1有着相似的ωRNA相互作用界面、在关键的ωRNA区域共享折叠模式。这种一致性表明不同Fz1蛋白之间存在保守的RNA引导的DNA靶向机制。但与此同时，这3种蛋白之间也有着不同的结构特征，突出了Fanzor蛋白家族内的多样性。一个例子就是来自藻类的GtFz1，它的催化三联体中有一个独特的N残基。与SpuFz1相同位置经典的D残基相比，GtFz1的N残基增强了蛋白的DNA切割活性。此外，寄生真菌的PpFz1有着独特的FRI结构域，这种结构域表明Fz1蛋白可能在寄生真菌的寄生关系中起到重要作用，通过促进转座子介导的基因转移实现对真菌的寄生。 ▲GtFz1的结构特征（图片来源：参考资料[1]）同时，Fanzor蛋白的DNA识别、切割机制也有了新发现。尽管Fanzor和Cas12都是从TnpB家族进化而来的，但两者的DNA识别、切割机制存在明显差异。研究团队发现，Fz1中额外的REC结构域结构对加载到RuvC结构域上的靶DNA的R-loop稳定有贡献。REC结构域对DNA解旋机制和R-loop调控的适应，可能对Fanzor蛋白在真核细胞复杂染色质环境中的功能至关重要。总之，这些研究揭示了Fanzor蛋白的作用机制、加深了对这类蛋白的理解，也为开发更强大的基因编辑工具奠定了基础。基因编码新发现：细菌的“保命”机制而在日前上线的一篇Science论文中，张锋团队则是挑战了教科书对蛋白质编码基因的传统定义。在传统观念里，蛋白质编码基因需要沿着DNA序列线性编码。但张锋团队的最新研究以及本月早先时间的另一篇Science论文（通讯作者为哥伦比亚大学Samuel Sternberg教授）共同发现，一些细菌的抗噬菌体蛋白并非通过这种传统方式得到编码。在这些细菌中，DNA首先被转录为非编码RNA，随后通过滚环逆转录反应转换回DNA。接下来，这些新生成的DNA再被转录为编码蛋白的mRNA，生成阻止噬菌体感染的蛋白。利用RNA模板合成DNA的逆转录酶广泛存在于各种生命领域中。在细菌中，逆转录酶在抗噬菌体防御系统中十分重要，这种防御系统通过逆转录机制，帮助细菌抵御噬菌体感染。在最新研究中，张锋团队关注的肺炎克雷伯菌有一种含有逆转录酶的防御系统，名为DRT2。这一系统在噬菌体感染期间能够阻止细菌生长，从而阻止噬菌体复制。DRT2系统仅包含逆转录酶和非编码RNA（ncRNA），没有其他已知的蛋白质结构域或因子。那么，这一简约的系统是如何识别感染并导致细菌生长停滞的呢？ ▲DRT2核糖核蛋白复合物结构（图片来源：参考资料[2]）研究发现，DRT2系统编码了另一种蛋白质，但这个过程依赖于一系列出人意料的复杂事件。首先，逆转录酶利用ncRNA中的约120个碱基序列作为模板来生成互补DNA，但它们不会在一次逆转录后停止，而是跳回到120个碱基序列的起点，就像在循环播放一首歌一样，继续“滚环”反应。通过这个过程，可以生成包含多个重复模板序列的长互补DNA拷贝。这些重复的DNA序列包含细菌σ70启动子的两个序列基序。通过将连续DNA中的重复片段首尾相连，细菌从两个分离的片段组装出一个有效的启动子，从而驱动mRNA的转录。这个mRNA进一步编码一种被命名为Neo的蛋白质，该蛋白质的独特之处在于其开放阅读框（ORF）几乎没有终止密码子，因此可以生成非常长的蛋白质。 DRT2系统通过产生这种Neo蛋白质来阻止噬菌体感染。感染发生时，DRT2系统会启动第二条互补DNA链的合成，这一过程触发了Neo蛋白质的生产，Neo蛋白质迅速抑制细菌生长，从而阻止噬菌体利用宿主细胞资源进行复制。尽管目前尚不清楚DRT2如何感知噬菌体的存在，以及如何启动第二条DNA链的合成，但张锋团队的这一发现揭示了逆转录酶在细菌防御系统中的独特作用。这些新发现不仅丰富了我们对细菌防御机制的理解，也为基因编辑和生物技术应用提供了新的可能性。附：张锋教授近年顶刊成果回顾 1. 发现188个新型CRISPR系统在2023年的一篇《科学》论文中，张锋合作团队借助其开发的全新算法，从数十亿个蛋白质序列中发现了188个此前未知的新型CRISPR相关系统，并且可能将CRISPR系统的类型拓展至7大类。这一发现进一步证实CRISPR系统的多样性，并且有望带来新型基因编辑工具。 2. 全新蛋白质递送系统诞生张锋团队在2023年的一项《自然》研究中，以一些细菌天然具有的注射结构“胞外可收缩注射系统”（eCIS）为灵感，开发了一种全新的蛋白质递送系统，利用细菌“注射器”，将蛋白质注射到人类细胞中。这项技术未来有望在基因疗法、癌症治疗等一系列领域发挥作用。 3. 可编程的DNA修饰系统OMEGA 2021年，张锋团队一个月内在《科学》杂志连续发表两篇基因编辑领域的重要突破。在其中一项研究中，团队在细菌中鉴定出一类新的核酸酶，它们由转座子编码的RNA引导到目标位置切割DNA。经过设计，这些核酸酶可以用于在人类细胞中编辑基因。研究团队将这套可编程的DNA修饰系统命名OMEGA。这项突破有望推动基因组编辑技术的下一次革命。 4. 全新的mRNA递送技术在另一篇《科学》论文中，张锋团队筛选出自带RNA运输功能的PEG10蛋白，其有潜力被改造成运输RNA分子的工具。以PEG10为核心，研究人员们进一步开发了一种叫做SEND的系统，全名是“选择性内源性衣壳化的细胞递送”系统。这项全新的mRNA递送技术，有望给基因疗法领域带来颠覆性的变革。 5. 新一代RNA单碱基编辑工具在2019年的一篇《科学》论文中，张锋团队介绍了基于CRISPR系统开发出的一种新型RNA编辑工具。在2017年开发的“REPAIR”系统的基础上，张锋团队通过酶进化的方法，使“REPAIR”系统的关键酶ADAR2具有全新的功能——将胞嘧啶（C）转化为尿嘧啶（U），并且减少了脱靶效应。这项技术能以前所未有的方式，对RNA进行单碱基的编辑。 6. 利用“跳跃基因”精确插入DNA片段在2019年的另一篇《科学》论文中，张锋团队来了一款全新的CRISPR基因编辑工具，利用“跳跃基因”，让DNA片段插入基因组变得更加容易。大肠杆菌中的实验结果显示成功率达到80%，远高于经典CRISPR系统。通过“改正”的DNA序列来取代含有致病突变的序列，这项技术将为治疗某些遗传疾病提供极大的帮助。参考资料： [1] Xu et al., Structural insights into the diversity and DNA cleavage mechanism of Fanzor, Cell (2024), https://doi.org/10.1016/j.cell.2024.07.050 [2] Wilkinson et al., Phage-triggered reverse transcription assembles a toxic repetitive gene from a non-coding RNA, Science (2024), DOI: 10.1126/science.adq3977 [3] Osterman et al., Tricking a phage with reverse transcription, Science (2024), DOI: 10.1126/science.ads3638 本文来自药明康德内容微信团队，欢迎转发到朋友圈，谢绝转载到其他平台。如有开设白名单需求，请在“学术经纬”公众号主页回复“转载”获取转载须知。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

基因疗法

2024-07-11

·药融圈

投资9.8亿！浙江海之心年产5350吨高纯度心血管原料药及13亿粒制剂项目（EPA&DHA）

▲8月15-16日 NDC2024生物医药创新者峰会扫码报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。【原料药情报局】获悉：近日，关于浙江海之心制药有限公司年产5350吨高纯度心血管原料药95/98.13亿粒制剂建设项目在相关网站审批公示。项目基本情况项目名称：浙江海之心制药有限公司年产5350吨高纯度心血管原料药95/98.13亿粒制剂建设项目建设性质：新建建设单位：浙江海之心制药有限公司建设单位母公司：俊达集团&江苏海莱康生物科技有限公司建设地点：仙居县福应街道经济开发区现代工业集聚区春晖中路南侧建设周期：2024年7月至2026年7月建设内容及规模：项目总投资98000万元，总用地面积59931.00m2，总建筑面积59204.35m2，建设生产车间6幢，动力车间1幢，仓库5幢，罐区设置储罐10个（并预留10个），生产EPA70EE 3496t/a、EPA98 997.484t/a、DHA95 349.95t/a，EPA98制剂10亿粒/年，DHA95制剂3亿粒/年，产生副产品低沸鱼油3354.99t/a、食品鱼油（含DHA70EE）2534.60t/a、氯化银5.066t/a。 EPA最早于2012年被美国FDA批准上市，用于降低严重高甘油三酯血症（TG≥500mg/dl）成人患者的甘油三脂水平，是FDA批准的首个纯EPA处方药。2019年12月二十碳五烯酸乙酯（商品名：Vacsepa）获FDA批准，成为首个辅助他汀类降低高危患者心血管风险的药。高纯度EPA和DHA凭借其保健功能和对心血管疾病的治疗和预防功能，被广泛应用于饲料添加剂、保健品和药品等产品中。江苏海莱康生物科技有限公司是一家专注于高含量EPA/DHA产品研发、生产和销售的高科技企业，成立于2020年9月，坐落于江苏省苏州市昆山市。自2010年开始将深海提炼物进行深加工研究，在EPA（二十碳五烯酸乙酯）和DHA（二十二碳六烯酸乙酯）提纯领域已取得重大技术突破，EPA纯度可达98%以上，DHA纯度可达95%以上。拥有规模化生产高纯度DHA/EPA的先进生产技术，年生产能力3200吨。关于二十碳五烯酸乙酯二十碳五烯酸乙酯，也称为EPA乙酯,是一种Omega-3脂肪酸衍生物,其来源于二十碳五烯酸(EPA)。它在抗炎、心脑血管保健及促进心理健康等方面展示了广泛的应用价值。EPA-EE通过抑制炎症介质的产生、改善血脂谱、稳定斑块等多种机制发挥作用。自1990年以来，EPA-EE在全球范围内逐渐受到认可，并在2012年由Amarin公司的Vascepa（商品名）在美国FDA获得批准，作为降低动脉粥样硬化性疾病风险的处方药物。 2023年，中国市场也先后批准了两款基于二十碳五烯酸乙酯（IPE）的药物。2月，国为医药的"立瑞欣®"获批用于降低重度高甘油三酯血症患者的甘油三酯水平；6月，亿腾医药"唯思沛"获批上市，用以减少已通过他汀类药物治疗的患者的心血管事件风险。此外，诚意药业正推进1000吨EPA原料药产能的建设，仁普药业与新华制药达成战略合作，每年可向全球API客户提供数百吨的Omega-3原料药。 CDE原料药登记版权声明：本文转自原料药情报局，如不希望被转载的媒体或个人可与我们联系，我们将立即删除 8月15日 C馆C105 创新药中美双报如何制定研发策略策划人：邹灵龙康维讯生物，创始人、董事长&CEO 会议日程 09:00-09:30 TBD 曹国帅 | 天港医诺，研发负责人 09:30-10:00 抗体药物中美IND快速申报策略姜伟东 | 康抗生物，创始人&CEO 10:00-10:30 中美IND申请非临床研究要点贺全仁 | 艾博生物，药理毒理高级副总裁 10:30-11:00 中美申报CMC要点 Audrey Jia | 前FDA药学审评员、Data Revive创始人 11:00-11:30 中美双报生物分析策略与实操分享邹灵龙 | 康维讯生物，创始人、董事长&CEO 11:30-12:00 创新药中美双报项目进展分享嘉宾行程确认中 12:00-13:30 午餐 13:30-14:00 Immunogenicity Testing Strategy & Regulatory Expectation on Method Validation- FDA perspective 严皓珩 | 复宏汉霖，美国注册负责人，前FDA评审 14:00-14:30 出海申报的临床试验设计与数据管理杨修诰 | 石药集团，高级医学总监 14:30-15:00 支持出海的ADC毒素ADME研究朱明社 | 锐迪欧医药，首席科学官&首席顾问 15:00-15:30 中美药品电子申报 (eCTD)要点任翀 | 复宏汉霖，药政注册副总监 15:30-16:30 圆桌对话：创新药中美双报路径，如何从多维度评估价值回报? 1.创新药在中美两国市场准入策略？ 2.市场准入路径对药品价值的影响 3.进行临床试验时应考虑哪些关键因素？ 4.监管合规性对药品上市时间和成本的影响？ 5.如何识别和管理潜在风险？陈春麟 | 美迪西生物，创始人&CEO （更多嘉宾行程确定中）扫码报名参会【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

上市批准医药出海

2024-02-15

·PRNewswire

Embrace Heart Health and the Power of Walnuts During American Heart Month

New survey finds most Americans aren't eating enough walnuts to reap their heart health benefits FOLSOM, Calif., Feb. 15, 2024 /PRNewswire/ -- A new survey1 from California Walnuts just revealed that only one-fifth of Americans (19%) say they eat enough walnuts to support a diet for heart health. With their exceptional nutritional profile, Americans are missing out on a delicious and easy way to support a healthy heart. Heart disease remains the leading cause of death in the U.S.,2 but research has shown that simple dietary changes can have a significant impact on heart health. In recognition of American Heart Month, California Walnuts encourages Americans to embrace heart health by including walnuts in their daily diet. Over the past three decades, studies have demonstrated the cardiovascular benefits of walnuts, exploring how eating walnuts affects various factors related to heart health such as cholesterol, blood pressure, inflammation and blood vessel function. Not only do walnuts help maintain healthy cholesterol levels,3,4 but they are also a versatile, plant-based whole food that makes a delicious addition to any meal. Whether enjoyed in salads, main dishes or snacks, walnuts provide a buttery richness and satisfying texture. According to a nationally representative survey of U.S. adults1, three in five respondents (62%) say walnuts pair best with salads, followed by half (47%) saying dark chocolate pairs well with walnuts, creating a craveable, heart-smart snack combo. One ounce of walnuts is a powerhouse of important nutrients for optimal health, including 4 grams of protein and 2 grams of fiber. Walnuts are also the only tree nut that is an excellent source of the plant-based omega-3 alpha-linolenic acid (2.5g/oz), an essential fatty acid that may play a role in heart health.5,6 An easy way to estimate how much is the right daily serving of walnuts is to simply grab a handful (~1 oz). "Following a diet that supports heart health is important year-round and choosing foods, like walnuts, is a fundamental habit to build," said California Walnuts partner, Samantha Cassetty, MS, RD. "From salads and oatmeal to baked goods, walnuts enhance the taste of everyday favorites while offering numerous potential health benefits." To help incorporate more walnuts into your diet, Cassetty suggests the following: Eat a handful of walnuts every day. You don't even need to eat them in one sitting. You could toss a few into your morning oatmeal or yogurt at breakfast, add some to roasted veggies or salad dishes at lunch, crush them to use as a breading for fish or chicken at dinner, and include them into desserts. Incorporate more whole, plant-based foods. Many simple ways exist for incorporating whole, plant-based options like walnuts, oats, quinoa, fruits, vegetables and seeds into your everyday diet. While stocking your refrigerator with fruits and vegetables, don't forget walnuts. They are nutritious while also being versatile and great tasting. Limit your intake of added sugars. To promote heart health, it is important to limit your intake of added sugars as they can raise triglyceride levels and promote inflammation, which both contribute to heart disease. Desserts are often a major source of added sugar in our diets, so it's beneficial to explore more nutritious options, like Walnut Stuffed Chocolate Covered Dates or No-Bake Walnut, Cocoa, Cherry Bars. Visit walnuts.org/american-heart-month for heart-healthy recipe ideas, tips for maintaining freshness and more information about walnuts and heart health. About the California Walnut Board The California Walnut Board (CWB) was established in 1948 to represent the walnut growers and handlers of California. The CWB is funded by mandatory assessments of the handlers. The CWB is governed by a Federal Walnut Marketing Order. The CWB promotes usage of walnuts in the United States through publicity and educational programs. The CWB also provides funding for walnut production, food safety and post-harvest research. References: 1. The California Walnut Commission conducted an online survey of 1,000 U.S. adults, ages 18+ in January 2024. The survey was conducted at a 95% confidence level with a +/-3% margin of error. 2.Tsao, C. et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation. 2023;147:e93–e621. 3. FDA approved claim: Supportive but not conclusive research shows that eating 1.5 ounces of walnuts per day, as part of a low saturated fat and low cholesterol diet, and not resulting in increased caloric intake, may reduce the risk of coronary heart disease. U.S. Food and Drug Administration, March 2004. One ounce of walnuts provides 18g of total fat, 2.5g of monounsaturated fat, 13g of polyunsaturated fat, including 2.5g of alpha-linolenic acid, the plant-based omega-3. 4. Kris-Etherton P. Walnuts decrease risk of cardiovascular disease: a summary of efficacy and biologic mechanisms. J Nutr. 2014; 10: 39:2S-8S. 5. U.S. Department of Agriculture, Agricultural Research Service. FoodData Central, 2019. fdc.nal.usda.gov. 6. Sala-Vila A, Fleming J, Kris-Etherton P, Ros E. Impact of α-Linolenic Acid, the Vegetable ω-3 Fatty Acid, on Cardiovascular Disease and Cognition. Adv Nutr. 2022 Oct 2;13(5):1584-1602. doi: 10.1093/advances/nmac016. PMID: 35170723; PMCID: PMC9526859. SOURCE California Walnut Commission

AHA会议

100 项与奥米加-3羧酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	奥米加-3羧酸	C10AX	DB09568

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高甘油三酯血症	美国	AstraZeneca Pharmaceuticals LP	2014-05-05

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉粥样硬化	临床3期	美国	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	中国	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	日本	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	澳大利亚	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	比利时	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	加拿大	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	捷克	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	丹麦	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	爱沙尼亚	AstraZeneca PLC	2014-10-30
动脉粥样硬化	临床3期	匈牙利	AstraZeneca PLC	2014-10-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01858948 (CTgov)	临床3期	代谢综合征 \| 躁郁症	19	Placebo+Quetiapine fumarate	襯遞獵襯製築遞築壓鑰(製選淵膚鬱餘廠選壓襯) = 壓齋鹹餘築齋繭積餘衊艱襯鑰壓醖範齋遞齋鬱 (膚積顧鬱醖壓蓋願糧鹹, 糧觸膚網顧艱壓鏇醖獵 ~ 夢構範築築繭鹹選鹽鑰) 更多	-	2022-11-25
NCT02104817 (STRENGTH, CTgov)	临床3期	高甘油三酯血症 \| 动脉粥样硬化	13,078	Epanova® (omega-3 carboxylic acids)	窪襯積窪鏇淵餘構鏇膚(觸網製窪廠淵憲夢積衊) = 製築膚糧選憲鹽淵鹽醖餘夢觸遞製觸網構築窪 (襯願窪壓範鬱襯齋廠網, 艱餘簾膚夢壓淵願膚糧 ~ 淵鏇壓鑰鏇選鑰鑰築憲) 更多	-	2021-07-28
NCT02947100 (CTgov)	临床1/2期	镰状细胞血症	4	SCD-Omegatex™	壓繭醖醖鏇膚顧蓋壓顧(艱鹽製顧憲淵壓膚艱夢) = 鏇鹹網艱廠餘繭願淵願夢選鏇襯壓顧顧廠選夢 (餘蓋壓願鏇餘鏇襯糧鹹, 艱齋鬱憲夢廠繭選憲鏇 ~ 鏇壓淵觸獵膚網願窪選) 更多	-	2020-10-19
NCT02463071 (CTgov)	临床3期	高甘油三酯血症	383	AZD0585 placebo+AZD0585 (AZD0585 2g Group)	鬱鑰齋壓醖繭積餘窪糧(齋構淵艱廠襯鬱鏇蓋膚) = 構膚襯醖蓋淵選壓夢築構簾廠選蓋衊積壓廠鬱 (膚觸齋觸襯壓鹽蓋醖淵, 糧憲網廠壓鹹壓繭壓膚 ~ 網鹽範遞鏇夢築鏇製壓) 更多	-	2018-10-01
				AZD0585 (AZD0585 4g Group)	鬱鑰齋壓醖繭積餘窪糧(齋構淵艱廠襯鬱鏇蓋膚) = 願鏇繭壓廠簾蓋鏇製範構簾廠選蓋衊積壓廠鬱 (膚觸齋觸襯壓鹽蓋醖淵, 範廠鹽遞製積構鬱窪鹽 ~ 糧範鬱廠範網鏇窪築獵) 更多
NCT02354976 (CTgov)	临床2期	高甘油三酯血症 \| 超重 \| 代谢功能障碍相关的脂肪肝病	78	Placebo	顧鏇繭淵觸襯襯顧觸齋(鬱顧醖憲觸襯鑰衊簾鑰) = 鬱窪鏇鑰網鏇製網鏇廠積築鹹衊蓋鹹夢夢鬱淵 (壓鹹積襯簾夢醖築獵鑰, 鏇願廠選鏇築醖構築衊 ~ 襯憲鬱壓製選範壓鑰繭) 更多	-	2018-09-25
NCT02057406 (OCEAN, CTgov)	临床3期	抑郁症 \| 心脏衰竭	108	2:1 EPA/DHA (2:1 EPA/DHA)	壓窪餘憲遞衊構遞鏇鏇(範鬱襯夢鹽顧糧網範鏇) = 淵艱醖膚積築壓製壓願憲繭鬱獵夢糧艱廠壓夢 (顧蓋簾鬱築蓋醖壓壓鏇, 觸蓋廠醖網範糧鹽觸簾 ~ 製夢觸鑰憲醖鑰構餘構) 更多	-	2017-06-12
				High EPA (High EPA)	壓窪餘憲遞衊構遞鏇鏇(範鬱襯夢鹽顧糧網範鏇) = 糧糧淵積窪獵醖鏇淵壓憲繭鬱獵夢糧艱廠壓夢 (顧蓋簾鬱築蓋醖壓壓鏇, 鬱觸獵糧襯製鏇繭積蓋 ~ 淵淵糧獵築鏇蓋簾淵選) 更多
NCT02359045 (CTgov)	临床1期	-	137	D1400147 (Treatment A_Part 1)	艱艱壓淵衊製夢製蓋範(網願鹽構襯繭艱選觸夢) = 鏇構選繭醖觸顧選鹹範艱鹹願積餘選顧範網築 (艱繭獵遞膚窪餘鑰鹹積, 遞簾憲糧顧壓蓋夢願壓 ~ 網鹹窪艱艱夢餘築餘顧) 更多	-	2017-05-01
				Omega-3-carboxylic acids (Treatment B_Part 1)	艱艱壓淵衊製夢製蓋範(網願鹽構襯繭艱選觸夢) = 鬱淵餘廠網積衊築製願艱鹹願積餘選顧範網築 (艱繭獵遞膚窪餘鑰鹹積, 夢夢觸廠齋鹽鏇襯窪網 ~ 鬱壓獵醖簾憲蓋糧艱鬱) 更多
NCT02279407 (EFFECT-II \| EFFECTII, CTgov)	临床2期	非胰岛素依赖型糖尿病2 \| 非酒精性脂肪性肝炎	223	placebo	製網壓餘廠簾鬱夢蓋鹽(衊積網蓋窪遞願窪壓選) = 簾構醖餘衊鬱壓鑰繭壓壓蓋襯齋淵窪製顧廠鏇 (壓餘願衊構網鹹獵網築, 鏇築衊觸壓窪選選鏇夢 ~ 簾憲憲選窪衊繭餘選願) 更多	-	2017-01-27
NCT02370537 (PRECISE, CTgov)	临床2期	2型糖尿病 \| 胰腺外分泌功能不全	490	OMACOR+EPANOVA (Low FEC (EPANOVA® and OMACOR®))	遞蓋築鏇齋鑰齋壓簾顧(鑰鹹鏇艱淵醖壓鹹餘鏇) = 襯窪蓋簾膚淵簾襯齋鬱糧簾鹹築願積繭壓餘衊 (廠觸餘襯簾夢選鑰顧遞, 積鹹鑰糧積壓製壓鹹齋 ~ 觸鏇鏇憲齋製鑰遞窪觸)	-	2017-01-20
				OMACOR+EPANOVA (Intermediate FEC (EPANOVA® and OMACOR®))	遞蓋築鏇齋鑰齋壓簾顧(鑰鹹鏇艱淵醖壓鹹餘鏇) = 艱鏇構齋觸餘製構廠觸糧簾鹹築願積繭壓餘衊 (廠觸餘襯簾夢選鑰顧遞, 糧窪夢獵網鹽膚構廠範 ~ 糧遞蓋衊製鑰艱淵膚壓)
NCT02372344 (CTgov)	临床1期	-	72	AZD0585 (Fasting)	範顧窪鹽艱醖夢齋願鬱(積膚襯壓餘築遞蓋衊醖) = 糧觸壓憲膚顧餘艱製繭獵憲繭餘糧鹹餘憲艱窪 (觸獵遞膚顧廠遞構範觸, 醖築顧鏇鬱淵糧繭夢繭 ~ 鏇膚繭窪鏇遞鏇鏇願齋) 更多	-	2016-05-16
				AZD0585 (Before Meal)	範顧窪鹽艱醖夢齋願鬱(積膚襯壓餘築遞蓋衊醖) = 鬱醖繭淵願鹽遞醖製製獵憲繭餘糧鹹餘憲艱窪 (觸獵遞膚顧廠遞構範觸, 簾衊積糧範製餘淵糧衊 ~ 顧網餘鏇夢鬱鹽網範簾) 更多